The pharmaceutical intermediates market size has grown strongly in recent years. It will grow from $33.37 billion in 2024 to $35.35 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to chemical synthesis advancements, drug development evolution, market demand and growth, research and development, regulatory compliance.
The pharmaceutical intermediates market size is expected to see strong growth in the next few years. It will grow to $47.01 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to biopharmaceutical innovation, precision medicine development, green chemistry initiatives, customized intermediates, pharmaceutical outsourcing trends. Major trends in the forecast period include continuous flow chemistry, increased automation and robotics, application of nanotechnology, biocatalysis and enzyme engineering, and strategic supply chain management.
The anticipated increase in the prevalence of chronic diseases is poised to drive the growth of the pharmaceutical intermediates market in the foreseeable future. Chronic diseases, characterized by lasting three months or longer and having the potential to worsen over time, are on the rise due to factors such as an aging population, lifestyle changes, rapid urbanization, and insufficient preventive measures. In March 2022, the National Institute of Health reported that chronic kidney disorders are expected to affect 13.4% of the population, with an estimated 4.902 to 7.083 million individuals requiring renal replacement therapy for end-stage kidney disease (ESKD). Pharmaceutical intermediates play a vital role in developing medications used to manage chronic diseases, mitigating the escalating prevalence of such conditions and consequently driving the pharmaceutical intermediates market's growth.
The anticipated increase in pharmaceutical drug production is expected to drive the growth of the pharmaceutical intermediates market moving forward. Drug production involves the manufacturing process of pharmaceutical substances, medications, or drugs. These pharmaceutical drugs are complex molecules that undergo multiple synthesis steps. Pharmaceutical intermediates are the chemical compounds generated during these intermediate stages of the manufacturing process, particularly as more complex and targeted drugs are developed. For example, in November 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association representing the pharmaceutical industry in Europe, reported that total pharmaceutical production in Europe reached €390.0 billion ($422,803 million) in 2023, an increase from €363.3 billion ($393,857 million) in 2022. Consequently, the rise in pharmaceutical drug production is fueling the growth of the pharmaceutical intermediates market.
Leading companies in the pharmaceutical intermediates market are introducing new product lines, such as API Intermediates, to enhance their market position and profitability. API intermediates, which are chemical compounds used in the synthesis of active pharmaceutical ingredients (APIs), play a crucial role in producing medications for various therapeutic areas. In October 2023, Huateng Pharmaceutical Co. Ltd., a China-based pharmaceutical company, launched its Gastrointestinal API Intermediates product line. These intermediates serve as building blocks for pharmaceutical active ingredients used in medications treating gastrointestinal system disorders, including laxatives, 5-HT3 receptor antagonists, H2-receptor antagonists, and proton pump inhibitors.
Leading companies in the pharmaceutical intermediates market are concentrating on developing intermediates specifically for small-molecule drugs. These intermediates are essential in the synthesis of small-molecule drugs, acting as transitional products formed during various stages of the chemical manufacturing process before culminating in the final active pharmaceutical ingredient (API) or drug substance. For example, in March 2022, Sumitomo Chemical Co. Ltd., a Japan-based chemical firm, launched active pharmaceutical ingredients (APIs) and intermediates tailored for small-molecule drugs. This initiative aims to enhance the company's capacity to meet the increasing demand for small-molecule medications by offering a broader array of high-quality APIs and intermediates.
In March 2024, International Chemical Investors Group (ICIG), a Luxembourg-based chemical company, acquired Vasant Chemicals for an undisclosed sum. This acquisition is designed to strengthen WeylChem’s foothold in the global specialty chemicals market. The strategic partnership aims to provide added value for customers and stakeholders by merging the technologies and resources of both companies, thus advancing Vasant Chemicals' global expansion efforts. Vasant Chemicals is an India-based producer of pharmaceutical intermediates.
Major companies operating in the pharmaceutical intermediates market include BASF SE, Sanofi SA, Thermo Fisher Scientific Inc, Meck KGaA, Dishman Carbogen Amcis Ltd, Evonik Industries AG, Arkema Inc., Lonza Group AG, Wuxi AppTec co. Ltd, Aurobindo Pharma Lmited., Lianhe Chemical Technology Co. Ltd., Cambrex Corporation, Vertellus Holdings LLC., Hovione LLC, Hikal Ltd., Codexis Inc., Aceto Corporation, Interchem Corporation, Midas Pharma GmbH, Arbiom, Dextra Laboratories Ltd., A. R. Life Sciences, Ingenza Ltd, Chiracon GmbH, Dyadic International Inc., Elam Pharma Pvt Ltd, Yin-sheng Bio-tech Co. Ltd., Green Vision Life Sciences, Sibylla Biotech s.r.l., Pfizer CentreOne.
North America was the largest region in the pharmaceutical intermediates market in 2024. The regions covered in the pharmaceutical intermediates market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical intermediates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Pharmaceutical intermediates are chemical compounds or substances used in the synthesis and production of active pharmaceutical ingredients (APIs) or drug substances. These intermediates play a crucial role in the development and production of a wide range of drugs and therapeutic products, and they are utilized by pharmaceutical companies and research institutions.
The main types of pharmaceutical intermediates products include chemical intermediates, bulk drug intermediates, and other products. Chemical intermediates are compounds or substances produced during the manufacturing process of chemicals and find applications in various industries, including pharmaceuticals, agrochemicals, polymers, and specialty chemicals. Categories of pharmaceutical intermediates include branded drug intermediates and generic drug intermediates. The applications of pharmaceutical intermediates cover various drugs such as analgesics, anti-infective drugs, cardiovascular drugs, oral antidiabetic drugs, antimicrobial drugs, and others. The end-users of pharmaceutical intermediates include biotech and pharma companies, research institutions, and others.
The pharmaceutical intermediates market research report is one of a series of new reports that provides pharmaceutical intermediates market statistics, including pharmaceutical intermediates industry global market size, regional shares, competitors with a pharmaceutical intermediates market share, detailed pharmaceutical intermediates market segments, market trends, and opportunities, and any further data you may need to thrive in the pharmaceutical intermediates industry. This pharmaceutical intermediate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pharmaceutical intermediates market consists of sales of intermediates for API synthesis, API precursors, fine chemicals, and specialty chemicals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The pharmaceutical intermediates market size is expected to see strong growth in the next few years. It will grow to $47.01 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to biopharmaceutical innovation, precision medicine development, green chemistry initiatives, customized intermediates, pharmaceutical outsourcing trends. Major trends in the forecast period include continuous flow chemistry, increased automation and robotics, application of nanotechnology, biocatalysis and enzyme engineering, and strategic supply chain management.
The anticipated increase in the prevalence of chronic diseases is poised to drive the growth of the pharmaceutical intermediates market in the foreseeable future. Chronic diseases, characterized by lasting three months or longer and having the potential to worsen over time, are on the rise due to factors such as an aging population, lifestyle changes, rapid urbanization, and insufficient preventive measures. In March 2022, the National Institute of Health reported that chronic kidney disorders are expected to affect 13.4% of the population, with an estimated 4.902 to 7.083 million individuals requiring renal replacement therapy for end-stage kidney disease (ESKD). Pharmaceutical intermediates play a vital role in developing medications used to manage chronic diseases, mitigating the escalating prevalence of such conditions and consequently driving the pharmaceutical intermediates market's growth.
The anticipated increase in pharmaceutical drug production is expected to drive the growth of the pharmaceutical intermediates market moving forward. Drug production involves the manufacturing process of pharmaceutical substances, medications, or drugs. These pharmaceutical drugs are complex molecules that undergo multiple synthesis steps. Pharmaceutical intermediates are the chemical compounds generated during these intermediate stages of the manufacturing process, particularly as more complex and targeted drugs are developed. For example, in November 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association representing the pharmaceutical industry in Europe, reported that total pharmaceutical production in Europe reached €390.0 billion ($422,803 million) in 2023, an increase from €363.3 billion ($393,857 million) in 2022. Consequently, the rise in pharmaceutical drug production is fueling the growth of the pharmaceutical intermediates market.
Leading companies in the pharmaceutical intermediates market are introducing new product lines, such as API Intermediates, to enhance their market position and profitability. API intermediates, which are chemical compounds used in the synthesis of active pharmaceutical ingredients (APIs), play a crucial role in producing medications for various therapeutic areas. In October 2023, Huateng Pharmaceutical Co. Ltd., a China-based pharmaceutical company, launched its Gastrointestinal API Intermediates product line. These intermediates serve as building blocks for pharmaceutical active ingredients used in medications treating gastrointestinal system disorders, including laxatives, 5-HT3 receptor antagonists, H2-receptor antagonists, and proton pump inhibitors.
Leading companies in the pharmaceutical intermediates market are concentrating on developing intermediates specifically for small-molecule drugs. These intermediates are essential in the synthesis of small-molecule drugs, acting as transitional products formed during various stages of the chemical manufacturing process before culminating in the final active pharmaceutical ingredient (API) or drug substance. For example, in March 2022, Sumitomo Chemical Co. Ltd., a Japan-based chemical firm, launched active pharmaceutical ingredients (APIs) and intermediates tailored for small-molecule drugs. This initiative aims to enhance the company's capacity to meet the increasing demand for small-molecule medications by offering a broader array of high-quality APIs and intermediates.
In March 2024, International Chemical Investors Group (ICIG), a Luxembourg-based chemical company, acquired Vasant Chemicals for an undisclosed sum. This acquisition is designed to strengthen WeylChem’s foothold in the global specialty chemicals market. The strategic partnership aims to provide added value for customers and stakeholders by merging the technologies and resources of both companies, thus advancing Vasant Chemicals' global expansion efforts. Vasant Chemicals is an India-based producer of pharmaceutical intermediates.
Major companies operating in the pharmaceutical intermediates market include BASF SE, Sanofi SA, Thermo Fisher Scientific Inc, Meck KGaA, Dishman Carbogen Amcis Ltd, Evonik Industries AG, Arkema Inc., Lonza Group AG, Wuxi AppTec co. Ltd, Aurobindo Pharma Lmited., Lianhe Chemical Technology Co. Ltd., Cambrex Corporation, Vertellus Holdings LLC., Hovione LLC, Hikal Ltd., Codexis Inc., Aceto Corporation, Interchem Corporation, Midas Pharma GmbH, Arbiom, Dextra Laboratories Ltd., A. R. Life Sciences, Ingenza Ltd, Chiracon GmbH, Dyadic International Inc., Elam Pharma Pvt Ltd, Yin-sheng Bio-tech Co. Ltd., Green Vision Life Sciences, Sibylla Biotech s.r.l., Pfizer CentreOne.
North America was the largest region in the pharmaceutical intermediates market in 2024. The regions covered in the pharmaceutical intermediates market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical intermediates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Pharmaceutical intermediates are chemical compounds or substances used in the synthesis and production of active pharmaceutical ingredients (APIs) or drug substances. These intermediates play a crucial role in the development and production of a wide range of drugs and therapeutic products, and they are utilized by pharmaceutical companies and research institutions.
The main types of pharmaceutical intermediates products include chemical intermediates, bulk drug intermediates, and other products. Chemical intermediates are compounds or substances produced during the manufacturing process of chemicals and find applications in various industries, including pharmaceuticals, agrochemicals, polymers, and specialty chemicals. Categories of pharmaceutical intermediates include branded drug intermediates and generic drug intermediates. The applications of pharmaceutical intermediates cover various drugs such as analgesics, anti-infective drugs, cardiovascular drugs, oral antidiabetic drugs, antimicrobial drugs, and others. The end-users of pharmaceutical intermediates include biotech and pharma companies, research institutions, and others.
The pharmaceutical intermediates market research report is one of a series of new reports that provides pharmaceutical intermediates market statistics, including pharmaceutical intermediates industry global market size, regional shares, competitors with a pharmaceutical intermediates market share, detailed pharmaceutical intermediates market segments, market trends, and opportunities, and any further data you may need to thrive in the pharmaceutical intermediates industry. This pharmaceutical intermediate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pharmaceutical intermediates market consists of sales of intermediates for API synthesis, API precursors, fine chemicals, and specialty chemicals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Pharmaceutical Intermediates Market Characteristics3. Pharmaceutical Intermediates Market Trends and Strategies4. Pharmaceutical Intermediates Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Pharmaceutical Intermediates Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Pharmaceutical Intermediates Market34. Recent Developments in the Pharmaceutical Intermediates Market
5. Global Pharmaceutical Intermediates Growth Analysis and Strategic Analysis Framework
6. Pharmaceutical Intermediates Market Segmentation
7. Pharmaceutical Intermediates Market Regional and Country Analysis
8. Asia-Pacific Pharmaceutical Intermediates Market
9. China Pharmaceutical Intermediates Market
10. India Pharmaceutical Intermediates Market
11. Japan Pharmaceutical Intermediates Market
12. Australia Pharmaceutical Intermediates Market
13. Indonesia Pharmaceutical Intermediates Market
14. South Korea Pharmaceutical Intermediates Market
15. Western Europe Pharmaceutical Intermediates Market
16. UK Pharmaceutical Intermediates Market
17. Germany Pharmaceutical Intermediates Market
18. France Pharmaceutical Intermediates Market
19. Italy Pharmaceutical Intermediates Market
20. Spain Pharmaceutical Intermediates Market
21. Eastern Europe Pharmaceutical Intermediates Market
22. Russia Pharmaceutical Intermediates Market
23. North America Pharmaceutical Intermediates Market
24. USA Pharmaceutical Intermediates Market
25. Canada Pharmaceutical Intermediates Market
26. South America Pharmaceutical Intermediates Market
27. Brazil Pharmaceutical Intermediates Market
28. Middle East Pharmaceutical Intermediates Market
29. Africa Pharmaceutical Intermediates Market
30. Pharmaceutical Intermediates Market Competitive Landscape and Company Profiles
31. Pharmaceutical Intermediates Market Other Major and Innovative Companies
35. Pharmaceutical Intermediates Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Pharmaceutical Intermediates Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on pharmaceutical intermediates market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for pharmaceutical intermediates? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pharmaceutical intermediates market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product: Chemical Intermediate, Bulk Drug Intermediate, Other Products2) By Category: Branded Drug Intermediate, Generic Drug Intermediate
3) By Application: Analgesics, Anti-Infective Drugs, Cardiovascular Drugs, Oral Antidiabetic Drugs, Antimicrobial Drugs, Other Applications
4) By End-User: Biotech and Pharma Companies, Research Institutions, Other End-Users
Subsegments:
1) By Chemical Intermediate: Active Pharmaceutical Ingredients (APIs); Specialty Chemicals2) By Bulk Drug Intermediate: Precursor Chemicals; Intermediate Drug Substances
3) By Other Products: Biopharmaceutical Intermediates: Excipients; Pharmaceutical Additives
Key Companies Mentioned: BASF SE; Sanofi SA; Thermo Fisher Scientific Inc; Meck KGaA; Dishman Carbogen Amcis Ltd
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- BASF SE
- Sanofi SA
- Thermo Fisher Scientific Inc
- Meck KGaA
- Dishman Carbogen Amcis Ltd
- Evonik Industries AG
- Arkema Inc.
- Lonza Group AG
- Wuxi AppTec co. Ltd
- Aurobindo Pharma Lmited.
- Lianhe Chemical Technology Co. Ltd.
- Cambrex Corporation
- Vertellus Holdings LLC.
- Hovione LLC
- Hikal Ltd.
- Codexis Inc.
- Aceto Corporation
- Interchem Corporation
- Midas Pharma GmbH
- Arbiom
- Dextra Laboratories Ltd.
- A. R. Life Sciences
- Ingenza Ltd
- Chiracon GmbH
- Dyadic International Inc.
- Elam Pharma Pvt Ltd
- Yin-sheng Bio-tech Co. Ltd.
- Green Vision Life Sciences
- Sibylla Biotech s.r.l.
- Pfizer CentreOne
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 35.35 Billion |
| Forecasted Market Value ( USD | $ 47.01 Billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
